Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May:67:52-57.
doi: 10.1016/j.drugpo.2019.01.021. Epub 2019 Mar 18.

Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study

Stephanie Parent  1 , Seonaid Nolan  2 , Nadia Fairbairn  2 , Monica Ye  1 , Anthony Wu  1 , Julio Montaner  3 , Rolando Barrios  4 , Lianping Ti  5 ; STOP HIV AIDS Study Group
Collaborators, Affiliations

Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study

Stephanie Parent et al. Int J Drug Policy. 2019 May.

Abstract

Background: Co-prescribing benzodiazepines and opioids is relatively contraindicated due to the possible overdose risk. However, people living with HIV (PLWH) may have concurrent psychiatric and/or chronic pain diagnoses that may lead to the use of opioids and/or benzodiazepines for symptomatic treatment. Consequently, some PLWH may be at-risk for the health harms associated with the co-prescribing of these medications. Given this, the objectives of this study were to first examine the prevalence of opioids and benzodiazepines co-prescribing, and second, to characterize patient factors associated with the co-prescribing of opioids and benzodiazepines among PLWH in British Columbia (BC), Canada.

Methods: Using data derived from a longitudinal BC cohort, we used bivariable and multivariable generalized estimating equation models to establish the prevalence of a benzodiazepine and opioid co-prescription and determine factors associated with this practice.

Results: Between 1996 and 2015, 14 484 PLWH were included in the study and were followed for the entire study period. At baseline, 548 people (4%) were co-prescribed opioids and benzodiazepines, 6593 (46%) were prescribed opioids only, 2887 (20%) were prescribed benzodiazepines only, and 4456 (31%) were prescribed neither medication. A total of 3835 (27%) participants were prescribed both medications at least once during the study period. Factors positively associated with concurrent opioid and benzodiazepine prescribing included: depression/mood disorder [adjusted odds ratio (AOR) = 1.32; 95% confidence interval (CI) = 1.22-1.43] and anxiety disorder (AOR = 1.45; 95% CI = 1.27-1.66), whereas female sex (AOR = 0.76; 95% CI = 0.64-0.91) and substance use disorder (SUD) (AOR = 0.82; 95% CI = 0.74-0.90) were negatively associated with the outcome.

Conclusion: Our findings indicate that co-prescription of opioids and benzodiazepines was seen at some point during study follow-up in over a quarter of PLWH. Given the known risks associated with this prescribing practice, future research can focus on the outcomes of co-prescribing among this patient population and the development of strategies to reduce the co-prescribing of opioids and benzodiazepines.

Keywords: Benzodiazepines; Canada; Co-prescription; Opioids; People living with HIV; Polypharmacy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alford DP, Compton P, & Samet JH (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of Internal Medicine, 144(2), 127–134. - PMC - PubMed
    1. Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J, … Wittchen H-U (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology (Vol. 19). 10.1177/0269881105059253 - DOI - PubMed
    1. BC Centre for Excellence in HIV/AIDS. (2014). Drug treatment program and virology registry. BC Centre for Excellence in HIV/AIDS.
    1. British Columbia Centre for Disease Control. (2016). HIV/AIDS Information System (HAISYS). Clinical Prevention Services, British Columbia Centre for Disease Control; Retrieved from http://www.bccdc.ca/about/accountability/data-access-requests/public-hea...
    1. British Columbia Centre for Disease Control Public Health Laboratory. (2016). HIV laboratory testing datasets (tests: ELISA, Western blot, NAAT, p24, culture). Clinical Prevention Services, British Columbia Centre for Disease Control; Retrieved from http://www.bccdc.ca/about/accountability/data-access-requests/public-hea...

Publication types

MeSH terms